Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

PURPOSE: To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following cancer progression on abiraterone. PATIENTS AND METHODS: In this do...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweeney, Christopher J., Percent, Ivor J., Babu, Sunil, Cultrera, Jennifer L., Mehlhaff, Bryan A., Goodman, Oscar B., Morris, David S., Schnadig, Ian D., Albany, Costantine, Shore, Neal D., Sieber, Paul R., Guba, Susan C., Zhang, Wei, Wacheck, Volker, Donoho, Gregory P., Szpurka, Anna M., Callies, Sophie, Lin, Boris Kin, Bendell, Johanna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662871/
https://www.ncbi.nlm.nih.gov/pubmed/35363301
http://dx.doi.org/10.1158/1078-0432.CCR-21-2326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662871/
https://www.ncbi.nlm.nih.gov/pubmed/35363301
http://dx.doi.org/10.1158/1078-0432.CCR-21-2326

Ejemplares similares